Regulatory milestones

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) was up C$0.01 to C$1.42 and unchanged at $1.35 on NASDAQ last week after submitting an NDA to FDA for Solorel macimorelin (AEZS-130) to diagnose adult growth hormone deficiency (GHD).